Cost-Effectiveness Analysis of Robotically Assisted Laparoscopy for Newly Diagnosed Uterine Cancers

Newly Diagnosed ◽

Effectiveness Analysis ◽

Uterine Cancers ◽

Robotically Assisted Laparoscopy

Cost-effectiveness analysis of innovative therapy for patients with newly diagnosed hormone-sensitive metastatic prostate cancer

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2021.03.022 ◽

2021 ◽

Author(s):

Rémi Pelloux-Prayer ◽

Philomène Schiele ◽

Stéphane Oudard ◽

Gwenaëlle Gravis ◽

François Kleinclauss ◽

...

Keyword(s):

Prostate Cancer ◽

Cost Effectiveness ◽

Metastatic Prostate Cancer ◽

Newly Diagnosed ◽

Innovative Therapy ◽

Effectiveness Analysis ◽

Hormone Sensitive

Cost-effectiveness analysis of low-molecular-weight heparin versus aspirin thromboprophylaxis in patients newly diagnosed with multiple myeloma

Thrombosis Research ◽

10.1016/j.thromres.2016.08.008 ◽

2016 ◽

Vol 145 ◽

pp. 119-125 ◽

Cited By ~ 6

Author(s):

Emilie Chalayer ◽

Aurélie Bourmaud ◽

Fabien Tinquaut ◽

Franck Chauvin ◽

Bernard Tardy

Keyword(s):

Molecular Weight ◽

Multiple Myeloma ◽

Cost Effectiveness ◽

Low Molecular Weight Heparin ◽

Low Molecular Weight ◽

Newly Diagnosed ◽

P01.109 Tumor treating fields treatment for patients with newly diagnosed glioblastoma: a cost-effectiveness analysis for Sweden

Neuro-Oncology ◽

10.1093/neuonc/noy139.151 ◽

2018 ◽

Vol 20 (suppl_3) ◽

pp. iii256-iii256

Author(s):

G F Guzauskas ◽

B C M Wang ◽

A Kinzel ◽

C Proescholdt

Keyword(s):

Cost Effectiveness ◽

Newly Diagnosed ◽

Tumor Treating Fields ◽

Effectiveness Analysis ◽

Newly Diagnosed Glioblastoma

Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn’s disease

The European Journal of Health Economics ◽

10.1007/s10198-012-0430-7 ◽

2012 ◽

Vol 14 (6) ◽

pp. 853-861 ◽

Cited By ~ 25

Author(s):

Monia Marchetti ◽

Nicola L. Liberato ◽

Antonio Di Sabatino ◽

Gino R. Corazza

Keyword(s):

Crohn’S Disease ◽

Cost Effectiveness ◽

Crohn's Disease ◽

Newly Diagnosed ◽

Top Down ◽

Cost-effectiveness analysis of robotically assisted radical hysterectomy for newly diagnosed uterine cervical cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2015.01.318 ◽

2015 ◽

Vol 137 ◽

pp. 127 ◽

Cited By ~ 1

Author(s):

M.M. Leitao ◽

R. Keller ◽

V. Sioulas ◽

W.R. Narain ◽

D. Boccamazzo ◽

...

Keyword(s):

Cervical Cancer ◽

Cost Effectiveness ◽

Radical Hysterectomy ◽

Uterine Cervical Cancer ◽

Newly Diagnosed ◽

Cost-effectiveness analysis of fesoterodine flexible dose in newly diagnosed patients with overactive bladder in routine clinical practice in Spain

ClinicoEconomics and Outcomes Research ◽

10.2147/ceor.s111646 ◽

2016 ◽

Vol Volume 8 ◽

pp. 541-550 ◽

Cited By ~ 1

Author(s):

Carmen Peral ◽

Francisco Sanchez-Ballester ◽

Jose Maria Garcia-Mediero ◽

Jaime Ramos ◽

Javier Rejas

Keyword(s):

Clinical Practice ◽

Cost Effectiveness ◽

Overactive Bladder ◽

Routine Clinical Practice ◽

Newly Diagnosed ◽

Effectiveness Analysis ◽

Flexible Dose

Cost-effectiveness analysis of olaparib as a maintenance monotherapy for patients with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation: A United States payer perspective

Gynecologic Oncology ◽

10.1016/j.ygyno.2020.05.186 ◽

2020 ◽

Vol 159 ◽

pp. 140-141

Author(s):

D.R.G. Muston ◽

M.J. Monberg ◽

K. McLaurin ◽

A. Sackeyfio ◽

R. Hettle ◽

...

Keyword(s):

United States ◽

Ovarian Cancer ◽

Cost Effectiveness ◽

Advanced Ovarian Cancer ◽

Newly Diagnosed ◽

Effectiveness Analysis ◽

Payer Perspective

Cost-effectiveness analysis of brentuximab vedotin with chemotherapy in newly diagnosed stage III/IV Hodgkin lymphoma.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.6609 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 6609-6609 ◽

Cited By ~ 2

Author(s):

Scott F. Huntington ◽

Gottfried Raffael Von Keudell ◽

Amy J. Davidoff ◽

Cary Philip Gross ◽

Sapna A Prasad

Keyword(s):

Cost Effectiveness ◽

Hodgkin Lymphoma ◽

Brentuximab Vedotin ◽

Stage Iii ◽

Newly Diagnosed ◽

Cost-effectiveness analysis comparing “PARP inhibitors-for-all” to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2020.08.003 ◽

2020 ◽

Vol 159 (2) ◽

pp. 483-490 ◽

Cited By ~ 1

Author(s):

Rafael Gonzalez ◽

Laura J. Havrilesky ◽

Evan R. Myers ◽

Angeles Alvarez Secord ◽

Joseph A. Dottino ◽

...

Keyword(s):

Ovarian Cancer ◽

Cost Effectiveness ◽

Maintenance Therapy ◽

Parp Inhibitor ◽

Parp Inhibitors ◽

Advanced Stage ◽

Newly Diagnosed ◽

The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis

Translational Lung Cancer Research ◽

10.21037/tlcr-19-605 ◽

2020 ◽

Vol 9 (5) ◽

pp. 1770-1784

Author(s):

Bin Wu ◽

Shun Lu

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Newly Diagnosed ◽

Small Cell Lung ◽

Effectiveness Analysis ◽

Effect Of Pd